The US Congress is readying votes on a sprawling bill that would restrict US outbound investment to China in sensitive sectors as well as federal government contracting with Chinese biotechnology companies, two controversial measures that were left out of similar legislation last year.
The provisions were included in a compromise defence bill released on Sunday after months of negotiation.
